Aurobindo receives FDA nod for generic Anafranil
Aurobindo’s clomipramine hydrochloride capsules are indicated for the treatment of obsessions and compulsions in patients with OCD.
Aurobindo has received the Food and Drug Administration’s permission for clomipramine hydrochloride capsules in dosage strengths of 25 mg, 50 mg and 75 mg.
Aurobindo’s clomipramine hydrochloride capsules, which are the generic of SpecGx’s Anafranil, are indicated for the treatment of obsessions and compulsions in patients with Obsessive-Compulsive Disorder.
[Read more: Aurobindo obtains FDA OK for 2 generics]
Clomipramine hydrochloride capsules have a market value of roughly $18 million for the 12 months ending April 2023, per IQVIA.
[Read more: Aurobindo receives FDA approval for 3 generics]